Evidence map›Paper›PMID 27111571›Full record

ArticleAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2016

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Ignacio F Mata, Marie Y Davis, Alexis N Lopez, Michael O Dorschner, Erica Martinez, Dora Yearout, Brenna A Cholerton, Shu-Ching Hu, Karen L Edwards, Thomas D Bird and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. LRRK2 and Parkinson's disease: from genetics to targeted therapy.Annals of clinical and translational neurology · 2023
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Variable frequency ofNPJ Parkinson's disease · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ignacio F MataVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Marie Y DavisVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Alexis N LopezDepartment of Medicine, University of Michigan, Ann Arbor, Michigan.
Michael O DorschnerDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington.
Erica MartinezVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Dora YearoutVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Brenna A CholertonVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Shu-Ching HuVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Karen L EdwardsDepartment of Epidemiology, University of California, Irvine, California.
Thomas D BirdVeterans Affairs Puget Sound Health Care System, Seattle, Washington.
Cyrus P ZabetianVeterans Affairs Puget Sound Health Care System, Seattle, Washington. zabetian@u.washington.edu.
University of Washington · USUniversity of California, Irvine · USUniversity of Michigan · USVA Puget Sound Health Care System · US

Funding

SPECIFICITY OF OXYGEN DNA DAMAGE AND MUTAGENESISP01AG001751 · NIA · UNIVERSITY OF WASHINGTON · PI CAMPBELL, MATTHEW D · 1985 to 2021
$29.6M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
GENETIC APPROACHES TO AGING RESEARCHT32AG000057 · NIA · UNIVERSITY OF WASHINGTON · PI RABINOVITCH, PETER S · 1985 to 2019
$14.2M
Using Multiplex Families to map Genes that Modify Susceptibility and Age at OnsetR01NS065070 · NINDS · UNIVERSITY OF WASHINGTON · PI ZABETIAN, CYRUS P · 2009 to 2012
$2.0M
Genetic Risk Factors for Parkinson's DiseaseI01BX000531 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI ZABETIAN, CYRUS P · 2009 to 2013
–
Genetic Studies of Neurologic and Dementing DisordersI01CX001006 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI BIRD, THOMAS DWIGHT · 2014 to 2017
–
BLRD VA I01 BX000531CSRD VA I01 CX001006NIA NIH HHS P01 AG001751NIA NIH HHS T32 AG000057NINDS NIH HHS P50 NS062684NINDS NIH HHS R01 NS065070
6 · The paper itself

Abstract

Mutations in the LRRK2 gene result in autosomal dominant, late onset Parkinson's disease (PD). Three such mutations (p.R1441C, p.R1441G, and p.R1441H) are known to occur within codon 1441, and haplotype analyses indicate that each one has arisen independently on multiple occasions. We sequenced the entire coding region of 18 casual genes for PD or other parkinsonian neurodegenerative disorders in the proband of a family with autosomal dominant PD. We discovered a new missense mutation in the LRRK2 gene, c.4321C>A (p.R1441S). The mutation was predicted to be highly deleterious in silico (Combined Annotation Dependent Depletion score of 25.5) and segregated with disease in the pedigree. The clinical characteristics of affected family members were similar to those described in PD families with other mutations in LRRK2 codon 1441 and included resting tremor, rigidity, bradykinesia, unilateral onset, and a good response to levodopa. Age at onset ranged from 41 to 76. Two of the affected members of the pedigree underwent detailed, longitudinal neuropsychological testing, and both displayed evidence of mild cognitive deficits at or slightly preceding the onset of motor symptoms. LRRK2 p.R1441S represents the fourth pathogenic mutation observed within codon 1441 and its discovery adds to the remarkable complexity of a mutational hotspot within the ROC domain of the LRRK2 protein. © 2016 Wiley Periodicals, Inc.

Indexed as

AgedDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHaplotypesHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedMutation, MissenseParkinson DiseasePedigreeRisk FactorsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humangeneticsmovement disordersneuropsychological

Identifiers

PMID27111571
PMCPMC5028305
OpenAlexW2344183734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.